2024-01-29 10:45:00 ET
Summary
- MoneyShow presents top investment ideas for 2024 from their contributors.
- This year’s edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth stocks, as well as ETF recommendations that target commodities, cryptocurrencies, and fixed income.
- Part 3 of this series includes Celldex Therapeutics, Charles Schwab, Corning, CTO Realty Growth and Cullen/Frost Bankers, among others.
MoneyShow’s top contributing analysts, strategists, and newsletter editors share their investment recommendations for the year ahead. See Part 2 here .
Celldex Therapeutics
By John McCamant, Editor of The Medical Technology Stock Letter
Celldex Therapeutics ( CLDX ) is one of our top picks for 2024. The recently reported 208-patient trial with the first-ever subcutaneous ((SC)) version of CLDX’s barzo in CSU confirmed that it is the Best-In-Class compound with the fastest onset and most durable efficacy in mast cell blocking.
All three doses had high statistical significance, (p<0.0001), improvement at 12 weeks. A p<0.05 is statistically significant and the barzoSC data hit the ball out of the park.
As its clinical profile continues to come to fruition, barzo is by far the leader in mast cell inhibition - hence the superior data. More details of the Celldex CSU trial will be at AAAAI in February 2024. But with its own recent and very successful clinical trial data combined with the clinical and regulatory setbacks for three potential competitors in just the past month or so, barzolvolimab’s position as the Best-In-Class compound is becoming even more evident than ever....
Read the full article on Seeking Alpha
For further details see:
MoneyShow's Best Investment Ideas For 2024: Part 3